Jorge Conde is a General Partner at Andreessen Horowitz, leading investments at the intersection of biology, computer science, and engineering across therapeutics, diagnostics, tools, and software. He serves on the boards of Asimov, Cartography, Dyno, Earli, Komodo Health, Octant Bio, Tome Biosciences, and Vicinitas.

Jorge cofounded and served as CEO of Knome, a human genome interpretation company acquired by Tute Genomics in 2015. He previously held multiple C-suite roles at Syros Pharmaceuticals (NASDAQ: SYRS) as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer, and worked as a biotechnology investment banker at Morgan Stanley.

Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from Johns Hopkins University. He was named a Henry Crown Fellow at the Aspen Institute in 2015 and recognized as one of the top 35 young innovators by MIT Technology Review.

Jorge joined Andreessen Horowitz as a General Partner in 2017, focusing on the Bio + Health team with over 20 years of experience in leading, building, operating, and investing in life sciences and healthcare companies. He has made investments ranging from seed to late-stage across multiple biotech and healthcare IT companies.

Jorge leads investments in companies advancing AI-driven drug discovery, computational medicine, and gene therapies, helping build the future of healthcare through technology convergence. His portfolio companies are transforming oncology research, autoimmune disease treatment, and precision medicine at scale.